Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
Summarize this article with:
SA Transcripts157.32K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call December 11, 2025 9:00 AM EST Company Participants Kate BenderCristian Massacesi - Executive VP, Chief Medical Officer & Head of DevelopmentLynelle Hoch - President of Cell Therapy OrganizationRosanna RicafortMonica Shaw Conference Call Participants Mary Kate DavisMatthew Phipps - William Blair & Company L.L.C., Research DivisionLuisa Hector - Joh. Berenberg, Gossler & Co. KG, Research DivisionSteve Scala - TD Cowen, Research DivisionCourtney Breen - Sanford C. Bernstein & Co., LLC., Research DivisionDavid Amsellem - Piper Sandler & Co., Research DivisionZachary Dunn - Guggenheim Securities, LLC, Research DivisionKripa Devarakonda Presentation Operator Welcome to the Bristol-Myers Squibb Hematology Drug Development Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Kate Bender, Investor Relations. Please go ahead.
Kate Bender Good morning. This is Kate Bender from Bristol-Myers Squibb, Investor Relations. And I'd like to thank you for joining us today to discuss our progress across key programs that are expected to shape the future of hematology treatments. It's exciting news for patients and the company, and we have a lot to talk about. I'm joined by Cristian Massacesi, our Chief Medical Officer and Head of Global Drug Development, who will take you through our slide presentation. Following the presentation, 3 of our leaders will join Christian for Q&A. Lynelle Hoch, President of our Cell Therapy Organization; Monica Shaw, Senior Vice President of Oncology Commercialization; and Rosanna Ricafort , Vice President of Hematology and Cell Therapy Global Drug Development. On Slide 2, please note that we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our SEC filings Recommended For You